This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?
by Zacks Equity Research
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy
by Zacks Equity Research
Allurion (ALUR) announces positive weight loss data for its gastric balloon technology.
Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure
by Zacks Equity Research
Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.
3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
HAE vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Patterson Companies' (PDCO) Launch to Boost Insurance Workflow
by Zacks Equity Research
Patterson Companies' (PDCO) latest offering is likely to offer customers additional options for their electronic insurance processing and patient billing statement workflow.
HealthEquity (HQY) Gains 25.3% YTD: What's Driving the Rally?
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
by Zacks Equity Research
Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.
McKesson (MCK) Gains 26% YTD: What's Driving the Rally?
by Zacks Equity Research
McKesson's (MCK) shares have risen year to date on the back of strong fundamentals. Rising volumes of prescription and specialty drugs boost the top line.
DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?
by Zacks Equity Research
DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Boston Scientific (BSX) closed at $77.41, indicating a +0.34% shift from the previous trading day.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
by Zacks Equity Research
Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
by Zacks Equity Research
Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.
Here's Why You Should Hold McKesson (MCK) in Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Veeva Systems' (VEEV) Vault EDC to Boost Tigermed's Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to streamline key processes to accelerate study builds and make mid-study amendments with no downtime.
DaVita (DVA), Nuwellis Extend Pilot Collaboration for Aquadex
by Zacks Equity Research
DaVita (DVA) extends its pilot collaboration with Nuwellis to conduct additional testing of the Aquadex ultrafiltration treatment for adult patients suffering from congestive heart failure and related conditions.
Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Intuitive Surgical (ISRG) Gets FDA Nod for da Vinci's New Label
by Zacks Equity Research
Intuitive Surgical (ISRG) announces the FDA clearance of revised da Vinci Xi and X Labeling on Radical Prostatectomy.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Indrajit Bandyopadhyay
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $76.12, marking a +0.3% move from the previous day.
Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.